CMS fee schedule a ‘meaningful positive’ for Quanterix, says Leerink

Leerink notes that CMS released a set of preliminary determinations for the clinical lab fee schedule, including having crosswalked Quanterix’s (QTRX) LucentAD Complete test to a $897 price. While coverage of blood biomarkers remains limited, the firm calls the pricing on CLFS a “meaningful positive” for Quanterix and believes average selling prices could see further upside if the company obtains ADLT status. The firm has a Market Perform rating on Quanterix shares.